Over the past 30 years, monoclonal antibody ((mAb)) therapies have revolutionized medicine. mAb therapy uses mAbs to specifically bind to target cells or proteins to stimulate the immune system to attack diseased cells. About 30 therapeutic monoclonal antibodies are marketed in the United States and Europe for a variety of indications.. mAb therapy has shown great promise as a treatment for rheumatoid arthritis, multiple sclerosuis, Alzheimer's disease, and different types of cancers.
The marketing research firm, BCC Research, found that the global market for mAbs was estimated at $44.6 billion in 2011. With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: